PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor
Name:
Revised CIR-19-0072R-FINAL.pdf
Size:
1.144Mb
Format:
PDF
Description:
Final Accepted Manuscript
Affiliation
Univ Arizona, Coll Pharm, Dept Pharm Practice & SciUniv Arizona, Ctr Canc
Univ Arizona, Coll Med, Dept Med
Univ Arizona, Coll Med, Dept Med Imaging
Issue Date
2019-09-01
Metadata
Show full item recordPublisher
AMER ASSOC CANCER RESEARCHCitation
Davis, L. E., Nicholls, L. A., Babiker, H. M., Liau, J., & Mahadevan, D. (2019). PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor. Cancer immunology research, 7(9), 1396-1400.Journal
CANCER IMMUNOLOGY RESEARCHRights
Copyright © 2019 American Association for Cancer Research.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
High-grade malignant peripheral nerve sheath tumors (MPNST) have a poor prognosis with limited responsiveness to systemic therapy. We document a case of a complete metabolic response to pembrolizumab monotherapy in metastatic disease. Tumor molecular profiling identified programmed-death ligand-1 (PD-L1) positivity. This characteristic provided a rationale for immune-checkpoint therapy. Treatment with pembrolizumab resulted in a complete metabolic response after four cycles of therapy. Patients with PD-L1-positive, metastatic MPNST may be candidates for immune-checkpoint therapy, which may produce a durable completere mission. Future study of anti-PD-1/PD-L1 therapy is warranted.Note
12 month embargo; published online: 1 September 2019ISSN
2326-6066PubMed ID
31383651Version
Final accepted manuscriptSponsors
CCSG P30 supplement from the NCIae974a485f413a2113503eed53cd6c53
10.1158/2326-6066.CIR-19-0072